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1. Introduction 
It is now clear that certain of the signal transduction 
pathways which relay messages fro,m the cell surface to 
the nucleus display a high level of evolutionary conserva- 
tion. Examples include mitogenic signalling in mammalian 
cells exposed to growth factors and hormones (reviewed in 
Refs. [l-3]), signalling pathways involved in vulva1 and 
eye development in C. elegans and Drosophila respec- 
* Corresponding author. 
tively [4,5], and the responses of budding yeast to mating 
pheromone (reviewed in Ref. [6]). All of these pathways 
utilise a kinase cascade which includes a member of a 
family of proteins referred to as mitogen-activated protein 
kinases (MARKS, also known as extracellular-regulated 
kinases or ERKs). The cellular targets of the MAP kinases 
in mammalian cells include the transcription factors c-Myc, 
ATF-2 and ELK-l reinforcing the concept that these pro- 
teins provide a key physical link in signal transduction 
from the cytoplasm to the nucleus. 
The most extensively characterised of the mammalian 
MAR kinases are the 42 kDa and 44 kDa isoforms (also 
0167-4889/95/$09.50 0 1995 Elsevier Science B.V. All rights reserved 
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referred to as ERK2 and ERKl respectively). These ser- 
ine/threonine kinases are unusual in requiring phospho- 
rylation on both tyrosine and threonine residues within the 
signature sequence T-E-Y (Thr-183 and Tyr-185 in mam- 
malian ERK2) for activity [7]. This dual phosphorylation is 
catalysed in vivo by a dual specificity (Tyr/Thr) kinase 
termed MAP kinase kinase (MAPKK) [8,9]. MAPKK is 
itself activated by phosphorylation on either of two serine 
residues by a MAP kinase kinase kinase (MAPKKK) 
[lO,ll]. In metazoans, this latter group of enzymes include 
members of the raf family of protein kinases, which lie 
downstream of activated ras proteins in the mitogenic 
signalling cascade, and t.he product of the c-mos proto- 
oncogene. 
Recently, the family of mammalian MAP kinases has 
been extended by the discovery that the ultraviolet (UV) 
radiation activated c&n kinase (JNKl) is a member of a 
novel subfamily of stress activated protein kinases 
(SAPK’s) which are 40-45% identical in sequence to the 
MAP kinases and contain the signature sequence T-P-Y 
[12,13]. In addition, a novel kinase which is responsible for 
activation of MAPKAP kinase 2 in response to heat shock 
or sodium arsenite and is also activated in response to 
osmotic stress [14,15] is most closely related in sequence 
to the yeast MAP kinase HOG-l. These MAP kinases all 
contain the signature sequence T-G-Y (see Table 1 for 
details). These findings, (coupled with earlier observations 
that ERKl and ERK2 can also be activated when cells are 
exposed to various stress, conditions including heat shock 
[ 16,171, osmotic stress [ :18], UV-radiation [ 191 X-irradia- 
tion, hydrogen peroxide and phorbol esters [20,21], suggest 
that we can regard these signalling pathways as being 
involved in a more general way in the processes by which 
cells sense, and respond lto, their external environment. 
about the way in which these kinases might subsequently 
be dephosphorylated and inactivated. However, in many 
cells the activation of MAP kinases is a transient event, 
even in the continuing presence of the stimulus which 
leads to activation. Examples of this latter phenomenon are 
seen following stimulation of rat phaechromocytoma 
(PC121 cells with epidermal growth factor [23] and stimu- 
lation of Chinese hamster lung fibroblasts with phorbol 
esters [24]. In addition, MAP kinase is dephosphorylated 
and inactivated within 30 min following fertilisation of 
Xenopus oocytes [25], suggesting that the inactivation of 
this key kinase is subject to cell cycle dependent regula- 
tion. All of these observations suggest that the inactivation 
of MAP kinases, like their activation, might be a tightly 
regulated event in cells and that the activity of the MAP 
kinases might be controlled by the balance of MAP kinase 
kinase and MAP kinase phosphatase activities. 
Understandably, most attention and excitement to date 
has been focussed on the identificaton of the key proteins 
which link activated cell surface receptors to this pathway 
(reviewed in Ref. [22]) and the elucidation of the molecu- 
lar mechanisms underlying the sequential phosphorylation 
and activation of the components of the MAP kinase 
cascade. In contrast, until recently very little was known 
This review describes the discovery and characterisation 
of a novel family of inducible genes encoding dual speci- 
ficity (Tyr/Thr) protein phosphatases with specificity for 
the inactivation of MAP kinases both in vitro and in vivo. 
The physiological significance of this mechanism for the 
regulated inactivation of MAP kinases in various cell types 
is discussed. In addition, there is an emerging complexity 
in the inactivation of MAP kinases. This involves firstly 
the increasing number of distinct MAP kinase family 
members which are currently being characterised, some of 
which are activated in response to conditions of cellular 
stress. This raises the question of substrate specificity 
among the MAP kinase phosphatases. Secondly, the mech- 
anism of MAP kinase inactivation may differ according to 
the cell type and the activating stimulus. This may relate to 
the subcellular location of the MAP kinase and may 
involve the activities of other tyrosine and/or 
serine/threonine protein phosphatases. 
2. Dual specificity protein phosphatases: the vaccinia 
VHl family 
Protein tyrosine phosphatases (PTPases) were first char- 
acterised following the isolation and cloning of the placen- 
Table 1 
The family of mammalian MAI? kinases 
Enzyme Molecular Signature Remarks Refs. 
mass (kDa) sequence 
ERKl 44 T-E.-Y “Classical” MAP kinase principally activated by hormones and growth factors. 1-3 
ERK2 42 T-E.-Y “Classical” MAP kinase principally activated by hormones and growth factors. l-3 
JNKl 44 T-P-Y UV-radiation activated human c-Jun kinase 12 
p54o 48 T-P-Y 
p54j3 48 T-P-Y The stress activated subfamily of rat c-Jun kinases or SAPK’s. Poorly activated by growth factors. 
Activated by stress and cytokines. The partial p54-y 
sequence is most closely related to human JNKl. 13 
P54Y a T-P-Y 
lZK/p38 42 T-C&Y Most closely related to the yeast kinase HOG-l. Activated by arsenite, heat shock and osmotic stress. 
Activates MAF’KAF’ kinase-2. 14,lS 
a Partial cDNA only. 
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CL100 
PAC-1 
VHR 
LGIT HFEGHYQYKSIPVEDNHKADIS 
CGIT HFEGLFRYKSIPVEDNQMVEIS 
LGIT RSFMHVNTNANFYKDSGITYLGIKANDTQEFNLS 
FMITHIL LIRKGYTLKNIPIDDDDVTDVLQYE'D 
LSFD NVAKEIPNLEFLI PPEMAHKIKYYHIEWTHTSKIVKDLS 
APSSEVKFK LPNSNINIIHIPLVDDTTTDISKYFDDVT 
CL100 
PAC-1 
VBR 
MSG5 
VHl 
EYSPRLVDFKKKPQR KPsVFJPNEwmlE 
LaAFVENPsF 
Fig. 1. Amino acid sequence similarities amongst the VHl-like phosphatases. Residues which arc identical to those in the vaccinia VHl sequence (bottom) 
are shown in bold and residues which are identical in all the sequences listed are marked with an asterisk. Residues which represent conservative 
substitutions relative to VHl are shaded. The PI’Pase active site sequence is boxed. For identification of individual proteins see abbreviations in text. 
tal enzyme, PTPlB, and the recognition of structural ho- 
mology between it and two tandem domains in the cyto- 
plasmic portion of the leukocyte common antigen CD45, a 
protein with intrinsic protein tyrosine phosphatase activity. 
These two enzymes are also representative of the two 
major classes of PTPase, namely the receptor type such as 
CD45 which contain a transmembrane spanning domain 
and the cytosolic or non-receptor type such as PTPlB 
which do not (reviewed in Ref. [26]). Subsequent sequence 
analysis of these and other members of the PTPase family 
led to the discovery that all of these enzymes contain an 
essential cysteine residue located within the highly con- 
served signature sequence [I/V] HCXAGXXR [S/T] G. 
Until recently, the presence of this motif served to define 
the specificity of these enzymes towards phosphotyrosine 
residues in substrate proteins. However, in 1991 a database 
search using the PTPase active site sequence lead to the 
discovery by Guan et al. of an open reading frame (VHl) 
in vaccinia virus [27]. This gene, which is of unknown 
function, is expressed at a late stage in viral infection and 
encodes a small (20 kDa) PTPase. Surprisingly, expression 
of this protein in bacteria and analysis of its activity 
towards various phosphorylated substrates revealed that, 
unlike other PTPases, VHl was a “dual specificity” pro- 
tein phosphatase in that it was able to dephosphorylate a 
number of proteins modified on either tyrosine or serine 
residues. 
Apart from the presence of a PTPase active site signa- 
ture sequence, the VI-D protein shows very little amino 
acid sequence homology with other members of the PT- 
Table 2 
Properties of the VHl family of protein phosphatases 
Gene Source Dual Remarks Refs. 
specificity 
CL100 Human Yes Inducible by oxidative/heat stress and growth factors. Substrate specificity 
for MAP kinases. 28,42&t 
3CH134/MKP-l/erp Mouse Yes Mouse CL100 homologue. Specificity towards MAP kinases demonstrated 
in vitro and in vivo. 29,30,43,50 
PAC-1 Human and Mouse Yes Mitogen inducible, nuclear, haematopoetic cell specificSpecificity towards 
MAP kinase. Closely related to CL100/3CH134/erp. 31,51 
VHR Human Yes Isolated by expression screening from human fibroblasts. Constitutive? 
Substrates unknown. 32 
YVHl S. cerevisiae Yes Inducible by nitrogen starvation. Null mutant grows very slowly. 
Substrates unknown. 33 
MSGS S. cereuisiae Yes Loss of MSGS diminishes the adaptive response to pheromone. 
Inactivates FUS3 kinase in vitro. 34 
PrP13 C. eugametos ND b Expressed in the early Gl phase of the ccl1 cycle. 
Hydrogen peroxide inducible. a 
BVP/ BVHl Baculovirus Yes Baculoviral phosphatase. Function unknown. 3536 
RVHl Raccoonpox virus Yes Representative of open reading frames found in several orthopoxviruses. 
function unknown. 35 
VHl Vaccinia virus Yes Expressed late in viral infection. Function unknown. 
Prototypic for this family of genes. 27 
a M.A. Haring, personal communication. b Not determined. 
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Pase family [27]. However, it is now clear that VHl is 
itself prototypic for a large and expanding sub-family of 
non-receptor type protein tyrosine phosphatases. At the 
present time this family includes several mammalian genes 
including the human enzyme CL100 [28] and its mouse 
homologue 3CH134/erp [29,30], the human and mouse 
PAC-1 proteins [31] and the human VHR gene [32]. In 
addition, two VHl like phosphatases have been isolated 
from S. cereuisiae, YVHl [33] and MSG5 [34] and VHl 
like phosphatases have been isolated from Chlamy- 
domonas eugumetos (MA. Haring, personal communica- 
tion), baculoviruses and orthopoxviruses [35,36]. 
There are amino acid sequence similarities between all 
of these proteins and VHl which extend over a putative 
catalytic domain of about 140 amino acids centred on the 
active sites of the proteins [28,32,33]. However, the region 
of greatest similarity between these phosphatases is located 
in a stretch of about 70 amino acids beginning just at the 
amino terminal side of the active site sequences (Fig. 1). 
The properties and activities of these VHl-like enzymes 
are summarised in Table 2. Of the VHl like phosphatases 
listed, four have been shown to be dual specificity Tyr/Ser 
phosphatases with properties similar to the vaccinia en- 
zyme. These are VHR, a human gene isolated by expres- 
sion screening of a fibroblast cDNA library [32], the yeast 
WHl protein [37] and the enzymes isolated from a bac- 
ulovirus and the orthopoxviruses [35,36]. It should be 
remembered that the VHl-like phosphatases are not the 
only group of PTPases wlhich are able to dephosphorylate 
both Tyrosine and Serine,/Threonine residues. The cdc25 
protein is responsible for the dephosphorylation of in- 
hibitory threonine and tyrosine residues in the catalytic 
domain of the p34cdc2/cyclin B kinase [38]. More re- 
cently, a novel dual specificity PTPase has been isolated 
by virtue of its association with certain of the cyclin-de- 
pendent kinases. This enzyme, referred to as Cdil [39] or 
RAP [40] contains a single copy of the PTPase active site 
but is otherwise dissimilar in amino acid sequence to any 
of the known PTPases. Cdil/KAP may be the first mem- 
ber of another distinct fa.mily of dual specificity protein 
phosphatases. 
3. The human CL100 protein and its mouse homologue 
3CH134 are specific phosphatuses for MAP kinases in 
vitro 
As part of a study designed to isolate human genes 
which are inducible by oxidative stress, a cDNA library 
prepared from human skin fibroblasts treated with hydro- 
gen peroxide was differe:ntially screened. This led to the 
isolation of a cDNA, dlesignated CLlOO, which corre- 
sponded to an inducible mRNA in cells following expo- 
sure to either oxidative stress or heat shock [28]. The 
CL100 cDNA was founld to encode a protein tyrosine 
phosphatase with sequence homology to VHl (Fig. 11. The 
nucleotide sequence of CL100 was also 86.6% identical to 
a mouse cDNA (3CH134) which had recently been charac- 
terised as a growth factor inducible immediate early gene 
[29]. The 3CH134 cDNA encodes a protein which is 
96.5% identical to the CL100 polypeptide and is clearly its 
mouse homologue. Of the other VHl-like phosphatases, 
the most closely related in amino acid sequence to CL100 
is PAC-1 (see Fig. 1) which was isolated as a mitogen 
inducible gene from human T-cells [31]. 
Not surprisingly, in view of the sequence similarity 
between CL100 and 3CH134, CL100 mRNA is also in- 
ducible by growth factors in serum starved human skin 
fibroblasts and 3CH134 mRNA is inducible by hydrogen 
peroxide and heat shock in mouse 3T3 cells [41] (also, T. 
Lewis and SM. Keyse, unpublished). The isolation of 
CL100 implicated for the first time a pathway involving 
tyrosine phosphorylation in the cellular response to stress 
and its independent isolation as an immediate early gene 
further suggested that the induction of this protein phos- 
phatase might be involved in signal transduction events 
which are common to both mitogenic and stress responses 
in human cells. 
The CL100 protein was expressed in bacteria and ob- 
tained in a highly purified form. This protein was able to 
hydrolyse p-nitrophenyl phosphate, a chromogenic sub- 
strate structurally related to phosphotyrosine [28]. In a 
study designed to identify candidate substrates for the 
CL100 phosphatase, its activity towards a range of model 
substrates containing either phosphotyrosine or phospho- 
serine/phosphothreonine was determined. Surprisingly, it 
was found that unlike VHl and certain other members of 
the VHl family, CL100 had no activity towards several 
proteins modified on either tyrosine or serine/threonine. 
These included substrates such as casein (P-Ser) and myelin 
basic protein (P-Tyr) against which the vaccinia phos- 
phatase was known to be active. The only substrate against 
which CL100 showed significant activity was activated 
recombinant 42 kDa (ERK2) MAP kinase [42]. These 
results demonstrated that CL100 was highly specific in its 
activity towards MAP kinase, at least in vitro, and strongly 
suggested that these proteins were the likely physiological 
substrates of the CL100 phosphatase in vivo. Similar re- 
sults indicating in vitro specificity towards MAP kinase 
were also obtained using the purified mouse 3CH134 
protein expressed in bacteria [43]. 
Further experiments utilising recombinant ERR2 which 
had been activated and 32P labelled by phosphorylation 
with purified MAP kinase kinase in the presence of [ y 32 P] 
ATP showed that co-incubation with increasing concentra- 
tions of CL100 protein lead to progressive loss of MAP 
kinase activity. This loss of activity was accompanied by 
complete dephosphorylation of the MAP kinase protein. 
This latter finding implied that the CL100 was acting to 
remove phosphate from both the tyrosine and the threonine 
residues required for MAP kinase activity. This was con- 
firmed by phosphoamino acid analysis of the MAP kinase 
protein [42]. Kinetic studies indicate that the tyrosine and 
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threonine residues of MAP kinase are dephosphorylated at 
the same rate. In addition, CL100 was capable of dephos- 
phorylating either phosphorylated residue in the absence of 
the other [42]. All of the above activities were abolished by 
mutagenesis of the conserved cysteine (Cys-258 to Ser) 
within the phosphatase active site of CLlOO. The above 
experiments were done using recombinant 42 kDa (ERK2) 
MAP kinase. However, CL100 also dephosphorylated and 
inactivated both 42 kDa (ERK2) and the 44 kDa (ERKl) 
MAP kinase isoforms isolated from PC12 cells stimulated 
with nerve growth factor indicating that both forms of 
MAP kinase are substrates for CL100 [42]. Dephosphoryla- 
tion of MAP kinase by CL100 protein expressed in bacte- 
ria has also been reported by Zeng and Guan [44]. It can be 
concluded from the above that the CL100 gene encodes a 
dual specificity (Thr/Tyr) phosphatase but that, unlike the 
vaccinia VHl protein which is active towards a broad 
range of substrate proteins containing either phospho- 
tyrosine or phosphoserine/phosphothreonine, the CL100 
enzyme is highly specific for activated MAP kinases. 
With respect to the strict substrate specificity of CLlOO, 
this is most reminiscent of the cdc25 phosphatase which 
activates the kinase ~34”~‘~ by dephosphorylating adja- 
cent threonine and tyrosine residues (Thr 14 and Tyr 15), 
thus triggering entry into mitosis (reviewed in Ref. [45]). 
The relationship between CL100 and cdc25 is further 
strengthened by the finding that CL100 and cdc25 share 
two short regions of amino acid sequence homology [46]. 
These lie in the amino terminus of CL100 and are outside 
the region of similarity between CL100 and VHl shown in 
Fig. 1. The significance of this similarity is not yet clear. 
However, the addition of CL100 protein to Xenopus oocyte 
extracts did not activate ~34”~“~ dependent histone Hl 
kinase activity, indicating that CL100 is unable to substi- 
tute for cdc25 in this system and further reinforcing the 
idea that CL100 is highly specific for MAP kinases [42]. 
4. In vivo activity and the family extended: the PAC-1 
protein is also a MAP kinase phosphatase 
The 42 kDa (ERK2) and 44 kDa (ERKl) MAP kinas- 
esare known to be downstream targets of activated ras 
protein and are believed to mediate at least part of its 
mitogenic signal (reviewed in [47]). In cell-free extracts 
from Xenopus oocytes, in which these signalling pathways 
are intact, addition of oncogenic [Va112] ras protein leads 
to activation of MAP kinase [48,49]. The addition of 
CL100 protein to these extracts was able to suppress ras 
activation of MAP kinase, suggesting that CL100 can 
overcome the activation of MAP kinase by MAP kinase 
kinase in response to ras 1421. These results suggest that 
the levels of active CL100 protein may be a critical 
determinant of MAP kinase activity and potentially capa- 
ble of modulating the transforming activity of activated ras 
oncogenes. The link between expression of CL100 and 
cellular proliferation is further reinforced by the finding 
that deregulated expression of the mouse CL100 homo- 
logue (3CH134 or erp) has a profoundly inhibitory effect 
on the growth of NIH3T3 cells [30]. Taken together the 
above results and in vitro data strongly suggest that the 
activated 42 kDa and 44 kDa MAP kinase isoforms are the 
physiological substrates for the CL100 phosphatase. Fur- 
thermore, the close sequence similarity between CL100 
and the PAC-1 protein suggests that CL100 might be the 
first member of a sub-family of VHl like phosphatases 
responsible for the regulation of MAP kinases. Recent 
work on the mouse homologue of CL100 (3CH134/erp) 
and the human PAC-1 protein described below have sup- 
ported these conclusions. 
When 3CH134 was expressed and immunoprecipitated 
from COS cells it was able, like CLlOO, to dephospho- 
rylate activated MAP kinase on both tyrosine and threo- 
nine residues in vitro [50]. However, further experiments 
have now provided evidence that this activity is responsi- 
ble for the dephosphorylation and inactivation of MAP 
kinase in vivo. Firstly, when serum starved mouse 3T3 
cells are stimulated by re-addition of serum, MAP kinase 
is transiently activated and the kinetics of MAP kinase 
inactivation in these cells coincides with the appearance of 
newly synthesised 3CH134 protein. Furthermore, the pro- 
tein synthesis inhibitor cycloheximide blocked both the 
synthesis of 3CH134 protein and the inactivation of MAP 
kinase. Secondly, electrophoretic analysis of phospho- 
tyrosine containing proteins showed that expression of 
3CH134 protein in COS cells leads to selective dephospho- 
rylation of MAP kinase. Finally, expression and immuno- 
precipitation of 3CH134 protein containing an inactivating 
mutation at the invariant cysteine of the PTPase active site 
revealed that it is recovered in a physical complex with 
activated MAP kinase. On the basis of these results 3CH134 
was renamed MAP kinase phosphatase-1 (MKP-1) [50]. 
Of the human VHl like phosphatases, PAC-1 is the 
most closely related to CL100 at the amino acid sequence 
level (Fig. 1) and like CL100 the PAC-1 protein is able to 
dephosphorylate and inactivate MAP kinase in vitro. 
Moreover, the induction of PAC-1 coincides with the 
inactivation of MAP kinase in Jurkat T cells [51]. The 
expression of PAC-1 is largely restricted to cells of the 
haematopoetic system, whereas CL100/3CH134 is ex- 
pressed in other cell types including skin fibroblasts, lung 
and brain [28,29,52]. This suggests that PAC-1 may repre- 
sent a tissue-specific isoform of the CL100 phosphatase. In 
addition, PAC-1 protein is found to be predominantly 
nuclear in mitogen-stimulated cells [31]. As MAP kinase is 
translocated to the nucleus, under certain conditions it is 
possible that this group of enzymes may all act within the 
cell nucleus. Preliminary experiments in my laboratory 
support this idea as transient expression of myc-tagged 
CL100 protein in COS-1 cells coupled with immunofluo- 
rescent detection shows that, like PAC-1, the CL100 pro- 
tein is localised primarily in the nucleus (Sneddon and 
Keyse, unpublished). 
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5. The physiological importance of MAP kinase inacti- 
vation in S. cerevisiae 
The budding yeast Saacharomyces cerevisiae responds 
to mating pheromone through a signalling pathway which 
includes the MAP kinase homologues FUS3 and KSSl. 
Activation of this pathway results in an initial block in the 
Gl phase of the cell cycle. However, in the continuing 
presence of pheromone, cells eventually adapt and resume 
mitotic growth. Doi et al.. [34] have recently isolated a 
gene (MSGS) which is (essential for this adaptation to 
occur. Overexpression of MSGS prevents the Gl block 
associated with constitutive activation of this signalling 
pathway and deletion of MrSG.5 results in diminution of the 
adaptive response to pheromone. The MGSS gene encodes 
a protein which is approximately 40% similar (22% identi- 
cal) to CL100 at the amino acid sequence level (Fig. 1). 
Purified MSGS protein expressed in bacteria is able to 
dephosphorylate activated FUS3 in vitro, resulting in loss 
of kinase activity and its phosphatase activity is essential 
for biological function as expression of a protein with an 
inactivating mutation at the essential cysteine of the PT- 
Pase active site resulted in loss of adaptation to pheromone. 
These findings coupled with genetic data which place 
MSGS downstream of SlTE7, which encodes the FUS3 
kinase kinase indicate that MSGS acts directly on the 
FUS3 kinase in vivo. Finally, just as the expression of the 
CL100/3CH134 and PAC-1 genes are induced by growth 
factors expression of the MSGS gene is induced in re- 
sponse to pheromone. This induction is dependent on the 
STE12 transcription factor which is known to require 
phosphorylation by FUS3 for its activity [53]. These results 
suggest a simple feedback. mechanism whereby activation 
of MAP kinases leads to transcriptional activation of MAP 
kinase phosphatases and hIAP kinase inactivation. 
6. Stress-activated members of the MAP kinase family 
and their inactivation: a question of specificity? 
Recently new members of the MAP kinase family have 
been identified in mammalian cells which, rather than 
being activated following exposure to growth factors, are 
preferentially activated tmder conditions of chemical or 
physical stress. These include the UV-radiation activated 
c-jun kinase JNKl [12], which is a member of a subfamily 
of stress-activated protein kinases (SAPKs) [13] and a 
novel kinase called reactivating kinase (RK) [14] or ~38 
[15] whose sequence is closest to HOG-l, a yeast kinase 
involved in adaptation to osmotic stress [54]. RK is acti- 
vated in response to heat ,shock, osmotic stress or sodium 
arsenite and is responsibsle for the activation of MAP 
kinase-activated protein (MAPKAP) kinase-2 and hence 
phosphorylation of the small heat shock proteins [14]. Thus 
far it is clear that, at least in vitro, CL100 is able to 
dephosphorylate and inactivate all of the MAP kinase 
homologues against which it has been tested. These in- 
clude the yeast FUS3 kinase (Keyse and Gartner, unpub- 
lished), the reactivating kinase [14] and the SAP kinase 
JNKl (D.W. Meek, personal communication). This raises 
the important question of specificity in vivo and the true 
physiological role of CLlOO. 
Some of the experimental evidence implicating 
CL100/3CH134 in the inactivation of ERKl and ERK2 in 
vivo is open to question. For instance, the demonstration 
of selective dephosphorylation of ERK2 among the spec- 
trum of tyrosine phosphorylated cellular proteins is based 
on detection with an antibody against phosphotyrosine 
[50]. However, this antibody does not recognise the c-jun 
kinase JNKl [12]. Furthermore, in the experiments demon- 
strating physical association between CL100/3CH134 and 
ERK2, transfection was used to express the phosphatase, 
probably at an abnormally high level. Finally, in mouse 
3T3 fibroblasts stimulated by serum growth factors, cyclo- 
heximide blocks induction of CL100 protein and leads to 
prolonged activation of ERK2 MAP kinase. However, in 
other cell types cycloheximide-blocked induction of CL100 
but did not cause sustained activation of ERKl or ERK2 
MAP kinases [55]. 
It should be remembered that CL100 was originally 
isolated as a stress-inducible gene [28] and it has subse- 
quently been shown that expression of the CL100 gene is 
potently induced by many of the cellular stresses which 
lead to activation of both the SAPKs and RK/p38. These 
include high fluences of UV-radiation (50-100 Jm-‘), 
high concentrations of sodium arsenite (200-1000 PM), 
osmotic stress and heat shock ([28] and SM. Keyse, 
unpublished). The fact that many of these stress condi- 
tions, although able to cause activation of ERKl and 
ERK2 in some cells do so only very poorly [14], argues 
against the involvement of CL100 in inactivating these 
enzymes and suggests that it may preferentially target the 
stress-activated isoforms of MAP kinase. However, it is 
still possible that there are additional CL100 like enzymes 
which are specific either for the inactivation of the stress- 
inducible MAP kinases or for ERKl and ERK2. There is 
certainly evidence from low stringency hybridisation stud- 
ies using CL100 as a probe that other, as yet uncharac- 
terised genes, which are closely related in sequence to 
CL100 are present in the human genome [56]. In addition, 
in Jurkat T-cells antibodies raised against the PAC-1 MAP 
kinase phosphatase cross-react with a mitogen inducible 
protein which is distinct from CLlOO, indicating the pres- 
ence of a second closely related phosphatase 1511. 
7. Inactivation of MAP kinase does not always involve a 
dual specificity phosphatase 
In certain cell types the activation and inactivation of 
ERKl and ERK2 MAP kinases occurs very quickly, often 
within a few minutes. One example of this is the transient 
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activation of MAP kinase activity by epidermal growth 
factor (EGF) in rat PC12 cells [23]. In these cells MAP 
kinase activity reaches a peak only 5 min after addition of 
EGF and declines rapidly within 30 min to 1 h. These 
kinetics of inactivation would appear to be too rapid for a 
response which requires transcription and translation of a 
dual specificity phosphatase before inactivation could take 
place. Recent experiments have now shown that the inacti- 
vation of MAP kinase in these cells does not require the 
synthesis of new proteins. The same is true in endothelial 
and adipose cell lines [55]. Surprisingly, even the slow 
inactivation of MAP kinase following the treatment of 
PC12 cells with NGF, which causes sustained activation of 
MAP kinase and its translocation to the nucleus is unaf- 
fected by inhibition of protein synthesis. This is despite the 
fact that all of these inducing conditions give rise to 
induction of CL100 mRNA and protein. However, in 
mouse 3T3 fibroblasts treated with EGF the inactivation of 
MAP kinase which occurs after 30 min of treatment was 
prevented by blocking the induction of CL100 confirming 
previous results obtained in this cell line [55]. 
In PC12 cells, biochemical studies have now identified 
protein phosphatase 2A (PP2A) activity as a rate-limiting 
step in the inactivation of MAP kinase, removal of phos- 
phate from threonine being required to enable a vanadate- 
sensitive phosphatase to then dephosphorylate the tyrosine 
residue [55]. Support for a mode of inactivation of MAP 
kinase which is independent of the induction of CL100 
like dual specificity phosphatases also comes from recent 
studies of MAP kinase inactivation in Xenopus and bud- 
ding yeast. MAP kinase becomes phosphorylated and acti- 
vated during progesterone-induced maturation of Xenopus 
oocytes to the unfertilized egg. However, within 30 min of 
fertilization, during interphase of the first mitotic cycle, 
MAP kinase is dephosphorylated and inactivated [25]. 
Sarcevic et al. [57] have purified MAP kinase phosphatase 
activities from Xenopus interphase extracts and these re- 
solved into an activity with the properties of the catalytic 
subunit of PP2A and a 47 kDa vanadate sensitive tyrosine 
phosphatase. Thus in this system there is no evidence for 
the involvement of a dual specificity MAP kinase phos- 
phatase in the inactivation of MAP kinase. In S. cereuisiae 
the MAP kinase homologue HOG1 is involved in an 
osmosensing signal transduction cascade [54]. Recently 
genetic studies have identified three genes encoding pro- 
tein phosphatases which dephosphorylate and inactivate 
the HOG1 kinase and PBS2, its activating kinase kinase. 
One of these, PTP2, encodes a tyrosine phosphatase which 
is apparently a specific HOG1 phosphatase [58]. 
8. The mechanism of MAP kinase inactivation may 
depend on its location in the cell 
It is clear from the studies described above that any 
model for the physiological inactivation of the MAP ki- 
SIGNAL 
INACTIVE ACTIVE 
Ser- 
ser_ MAPKK 0 
INACTIVE 
Fig. 2. Model for the inactivation of MAP kinases in the cytoplasm and 
the nucleus of stimulated cells. When cells are stimulated by growth 
factors it is envisaged that two types of response can occur. In certain cell 
types, stimulation will result in the transient activation of MAP kinase 
kinase (MAPKK) in the cytoplasm and subsequent activation of MAP 
kinase (MAPK). Under these conditions MAPK is not translocated to the 
nucleus and is quickly inactivated in the cytoplasm by protein phos- 
phatase 2A (PP2A) which dephosphorylates Thr-183 and by an as yet 
uncharacterised protein tyrosine phosphatase (PTP) which dephosphory- 
lates Tyr-185. In this scheme the activity of MAPK is determined by the 
balance of MAPKK activity and that of PP2A which is also responsible 
for inactivating MAPKK. However, under conditions where MAPK 
activation is sustained the enzyme translocates to the nucleus (Stippled 
arrow). Here it is protected from inactivation by PP2A and will remain 
active until dephosphorylated on both Thr-183 and Tyr-185 by one of the 
inducible dual specificity (Thr/Tyr) MAP kinase phosphatases such as 
CLlOO/MKP-1 or PAC-1. For full details see text. 
nases must take into account the existence of at least three 
separate types of MAP kinase phosphatases which differ 
both in structure and mode of action. Based on results 
which demonstrate that PP2A is a major component of the 
MAP kinase phosphatase activity present in PC12 cells 
and in endothelial and adipose cell lines, a model has been 
proposed in which the mechanism of inactivation of MAP 
kinase is dependent on whether it is located in the cyto- 
plasm or the nucleus [55]. The basic features of this model 
are summarised in Fig. 2. Briefly, stimuli such as treatment 
of PC12 cells with EGF which lead to a very rapid and 
transient activation of MAP kinase do not result in signifi- 
cant translocation of the kinase to the nucleus. The activity 
of the MAP kinase is therefore held in balance between the 
activities of MAP kinase kinase and PP2A in the cyto- 
plasm. Interestingly, PP2A is also the major activity re- 
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sponsible for the inactivation of MAP kinase kinase in 
PC12 cell extracts [55] and several lines of evidence point 
towards its involvement in the inactivation of MAP kinase 
kinases in vivo [59]. Therefore, PP2A may be responsible 
for the inactivation of both MAP kinase and MAPKK in 
the cytoplasm. A separate tyrosine phosphatase is impli- 
cated in the removal of phosphate from the tyrosine of 
MAP kinase but dephosphorylation of phosphothreonine 
by PP2A is the rate-limiting step [55]. 
In contrast to the above situation, the sustained activa- 
tion of MAP kinases by certain growth factors is accompa- 
nied by translocation of these kinases to the nucleus where, 
presumably, they act to phosphorylate the transcription 
factors which mediate the altered patterns of gene expres- 
sion associated with proliferation or differentiation [23,60]. 
This translocation separates MAP kinase from MAPKK 
which remains cytosolic [60] and as PP2A is also largely 
cytosolic, may protect MAP kinase from inactivation by 
this enzyme. Providing tlhat MAP kinase remains in the 
nucleus it will now remain active despite the inactivation 
of MAPKK and this is i:ndeed the situation after growth 
factor stimulation in 3T3 fibroblasts and endothelial cells 
[55]. Once in the nucleus MAP kinase might now be 
subject to regulated dephosphorylation by dual specificity 
(Thr/Tyr) phosphatases such as CLlOO/MKP-1 or PAC-1. 
The PAC-1 MAP kinase phosphatase is known to be 
located in the nucleus [31] and preliminary experiments 
indicate that this is also the case for CLlOO. The activity of 
the dual specificity phosp:hatases would leave MAP kinase 
in its ground state where it would then have to be re-ex- 
ported to the cytoplasm before it could be reactivated by 
MAPKK. 
9. Concluding remarks 
The discovery of inducible genes which encode dual 
specificity (Thr/Tyr) MAP kinase phosphatases has re- 
vealed an important new mechanism for the regulation of 
this kinase, which lies alt the heart of one of the major 
pathways involved in the transduction of signals from the 
cell surface to the nucleus. The fact that the genes encod- 
ing these enzymes are so highly conserved from verte- 
brates to yeast [34,56,61] indicates that this mechanism for 
the inactivation of MAP kinases, like the mechanism for 
activation, is universal. This opens up many new possibili- 
ties for the use of phosphatases such as CL100 as probes 
to determine the biological effects of MAP kinase activa- 
tion both in vitro and in vivo. Such work should allow us 
to gain fundamental insights into the precise role of MAP 
kinase-dependent phospheorylation in key areas such as 
development, cell proliferation, differentiation, and onco- 
genie transformation. New insights into CL100 function 
are already being revealed as induction of the CL100 gene 
has recently been linked with the induction of long term 
potentiation (LTP) in the bippocampus [62] and CL100 has 
been identified as a gene which is induced as part of an 
apoptotic response in rat prostate cells [63]. In the mean- 
time, many fundamental questions remain to be answered 
concerning the regulation and activity of these phospha- 
tases. These include (1) The elucidation of the mechanism 
by which the genes encoding CL100 and PAC-1 are 
transcriptionally activated by stress and growth factors. (2) 
The question of specificity of the mammalian 
CLlOO/MKP-1 and PAC-1 phosphatases for the various 
isoforms of MAP kinase, including those which are in- 
ducible by cellular stress. (3) The molecular basis for the 
extraordinary degree of substrate specificity of these phos- 
phatases. 
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